In this interview, Prof. Andrew Wei answers the following questions:

• What are the presenting symptoms of MDS and AML?
• How is a diagnosis of MDS or AML achieved?
• Why is it important to differentiate between MDS and AML?

Professor Andrew Wei is a clinical haematologist, National Health and Medical Research Council clinical fellow and co-stream lead for acute leukaemia and myelodysplastic syndromes at the Peter MacCallum Centre and the Royal Melbourne Hospital in Melbourne, Australia. read more

Prof. Wei discloses: Advisory board/panel fees from AbbVie, Agios, Amgen, Astellas, AstraZeneca, Beigene, Bristol Myers Squibb, Gilead, Janssen, Jazz, Novartis, Pfizer, Roche, Servier. Consultancy fees from AbbVie, Aculeus, Novartis, Servier, Shoreline. Grants/research support from AbbVie, Astex, AstraZeneca, Bristol Myers Squibb, Janssen, Novartis, Servier, Syndax [Amgen to institution]. Other financial or material support (royalties, patent, etc.) Prof. Wei is an employee of the Walter and Eliza Hall Institute (WEHI). WEHI receives milestone and royalty payments related to drug development. Current and past employees of WEHI may be eligible for financial benefits related to these payments. Prof. Wei receives such a financial benefit. Speaker’s bureau fees from AbbVie, Astellas, Bristol Myers Squibb, Novartis, Servier.

In this interview, Prof. Agnieszka Wierzbowska answers the following questions:

• What is the pathophysiology of MDS and AML and how is it linked to disease progression?
• How is MDS classified according to the latest guidelines?
• How do the updated guidelines impact patient management in MDS?
• How do the 2022 guideline updates affect a diagnosis of AML?

Prof. Agnieszka Wierzbowska is head of the Department of Hematology at the Medical University of Łódź, Copernicus Memorial Hospital in Łódź, Poland. read more

Prof. Wierzbowska discloses: Research grants from Jazz Pharmaceuticals. Honoraria from AbbVie, Astellas, Bristol Myers Squibb/Celgene, Gilead/Kite, Janssen, Novartis, Pfizer, Servier. Advisory board fees from AbbVie, Astellas, BerGenBio, Bristol Myers Squibb/Celgene, Gilead/Kite, Janssen, Novartis, Pfizer, Servier.

In this interview, Prof. Gert Ossenkoppele answers the following questions:

• What are the recent updates in the IPSS-M prognostic risk assessment for MDS and how do the IPSS-M and IPSS-R assessments compare?
• How does the use of IPSS-M impact patient management?
• What recent updates have been made to the prognostic risk guidelines for AML?
• What is the impact of recent changes to the AML guidelines on patient care?

Prof. Gert Ossenkoppele was appointed as professor of haematology at the VU University Medical Center in Amsterdam in 2003. He now has an honorary position as haematologist at the Amsterdam University Medical Center. read more

Prof. Ossenkoppele discloses: Advisory board fees from AGIOS, Amgen, Astellas, Bristol Myers Squibb, Celgene, Gilead, JAZZ Pharmaceuticals, Johnson & Johnson, Novartis, Pfizer, Roche, Servier. Consultancy fees from Celgene, Johnson & Johnson, Pfizer, Roche. Research support from Celgene, Johnson & Johnson, Novartis.